GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Innovent Biologics Inc (HKSE:01801) » Definitions » Goodwill-to-Asset

Innovent Biologics (HKSE:01801) Goodwill-to-Asset : 0.00 (As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Innovent Biologics Goodwill-to-Asset?

Goodwill to Asset ratio measures how much goodwill a company is recording compared to the total level of its assets. Innovent Biologics's Goodwill for the quarter that ended in Dec. 2023 was HK$0 Mil. Innovent Biologics's Total Assets for the quarter that ended in Dec. 2023 was HK$22,562 Mil. Therefore, Innovent Biologics's Goodwill to Asset Ratio for the quarter that ended in Dec. 2023 was 0.00.


Innovent Biologics Goodwill-to-Asset Historical Data

The historical data trend for Innovent Biologics's Goodwill-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Innovent Biologics Goodwill-to-Asset Chart

Innovent Biologics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Goodwill-to-Asset
Get a 7-Day Free Trial - - - - -

Innovent Biologics Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Goodwill-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Innovent Biologics's Goodwill-to-Asset

For the Biotechnology subindustry, Innovent Biologics's Goodwill-to-Asset, along with its competitors' market caps and Goodwill-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Innovent Biologics's Goodwill-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Innovent Biologics's Goodwill-to-Asset distribution charts can be found below:

* The bar in red indicates where Innovent Biologics's Goodwill-to-Asset falls into.



Innovent Biologics Goodwill-to-Asset Calculation

Goodwill to Asset ratio measures how much goodwill a company is recording compared to the total level of its assets.

It is calculated by dividing goodwill by total assets.

Innovent Biologics's Goodwill to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Goodwill to Asset (A: Dec. 2023 )=Goodwill/Total Assets
=0/22561.771
=0.00

Innovent Biologics's Goodwill to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Goodwill to Asset (Q: Dec. 2023 )=Goodwill/Total Assets
=0/22561.771
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Innovent Biologics  (HKSE:01801) Goodwill-to-Asset Explanation

If the goodwill-to-asset ratio increases, it can mean that the company is recording a proportionately higher amount of goodwill, assuming total assets are remaining constant. It is generally good to see a company increasing its assets regularly; however, if these increases are coming from intangible assets, such as goodwill, the increases may not be as good.

Increases in the goodwill-to-asset ratio might suggest that a company has been aggressively acquiring other firms or has seen its tangible assets decrease in value. When a large portion of total assets are attributable to intangible assets (such as goodwill), the company may be at risk of having that portion of its asset base wiped out quickly if it must record any goodwill impairments. Decreases in the goodwill-to-assets ratio suggest that the company has either written down some goodwill or increased its tangible assets.

Asset needs vary from industry to industry. This is why comparing goodwill-to-assets ratios is generally most meaningful among companies within the same industry. By comparing a company's goodwill to assets ratio to those of other companies within the same industry, investors can get a feel for how a company is managing its goodwill.


Innovent Biologics Goodwill-to-Asset Related Terms

Thank you for viewing the detailed overview of Innovent Biologics's Goodwill-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Innovent Biologics (HKSE:01801) Business Description

Traded in Other Exchanges
Address
168 Dongping Street, Suzhou Industrial Park, Jiangsu, Suzhou, CHN, 215123
Innovent Biologics, or Innovent, is one of the leading biotechnology companies in China. Listed on the Hong Kong Exchange in 2018, Innovent has eight commercialized oncology products and two commercialized non-oncology products as of August 2023. Its core asset is Tyvyt, a PD-1 inhibitor included in the National Reimbursement Drug Lists for the first-line treatment of five major cancers. Innovent has over 30 strategic collaborations with global pharmaceutical or biotech companies, such as Eli Lilly, Roche Group, Incyte, and others. It also has a wide spectrum of therapeutic targets in early clinical developments. Among its upcoming pipelines, the potential blockbuster is Mazdutide, a therapy for obesity and type 2 diabetes.
Executives
Jpmorgan Chase & Co. 2502 Approved lending agent
Yu De-chao Michael 2101 Beneficial owner
Temasek Holdings (private) Limited
Brown Brothers Harriman & Co. 2502 Approved lending agent
The Capital Group Companies, Inc. 2201 Interest of corporation controlled by you
Morgan Stanley 2201 Interest of corporation controlled by you
Citigroup Inc. 2201 Interest of corporation controlled by you
Shi Yi 2201 Interest of corporation controlled by you
Lav Asset Management (hong Kong) Limited 2102 Investment manager
Eight Roads Investments 2101 Beneficial owner
Fullerton Management Pte Ltd 2201 Interest of corporation controlled by you
Temasek Life Sciences Private Limited 2201 Interest of corporation controlled by you
Tls Beta Pte. Ltd. 2101 Beneficial owner

Innovent Biologics (HKSE:01801) Headlines

No Headlines